Dysmenorrhea — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for dysmenorrhea. 120 active patents protecting 7 drugs from 6+ originators. First major cliff: 2030. Daily refresh.

7
Approved drugs
120
Active US patents
63/100
Avg vulnerability
—
Annual revenue covered

Originators in Dysmenorrhea

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Exeltis Usa Inc 42 patents Pfizer Inc. (originally Searle/Pharmacia) 37 patents Hisamitsu Pharmaceutical Co., Inc 14 patents Generic (originally Boots Group) 14 patents Fdn Consumer 12 patents Mochida Pharmaceutical Co., Ltd. 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating dysmenorrhea. Each bar = one year. Y-axis scaled to peak year (32 patents).

14
27
3
28
23
29
28
30
32
31
4
32
2
33
1
34
10
36
1
40

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Slynd
DROSPIRENONE
 Exeltis Usa Inc 42 64 — 2028-01-15
Arthrotec
Diclofenac Sodium
 Pfizer 24 73 — 2027-03-22
Voltaren
DICLOFENAC
 Hisamitsu Pharmaceutical Co., Inc 14 57 — 2030-04-23
Advil
ibuprofen
 Generic (originally Boots Group) 14 70 — 2029-09-30
Celebrex
celecoxib
 Pfizer Inc. (originally Searle/Pharmacia) 13 51 — 2030-04-19
Jadelle
LEVONORGESTREL
 Fdn Consumer 12 48 — 2027-02-07
Natazia
DIENOGEST
 Mochida Pharmaceutical Co., Ltd. 1 75 — 2028-01-30

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12090231 Slynd method of use 81 2031-06-28
11951213 Slynd method of use 81 2031-06-28
11951213 Slynd method of use 81 2031-06-28
12090231 Slynd method of use 81 2031-06-28
8946292 Arthrotec method of use 80 2027-03-22
8871809 Arthrotec method of use 80 2027-10-17
8563613 Arthrotec method of use 80 2027-10-17
8153616 Natazia method of use 80 2028-01-30
8252838 Arthrotec method of use 80 2028-04-21
11478488 Celebrex method of use 76 2030-04-19

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
12004992 Jadelle composition of matter 0 2033-10-06
9012440 Celebrex composition of matter 10 2030-04-19
8598152 Celebrex composition of matter 10 2030-04-19
10245276 Celebrex composition of matter 10 2030-04-19
11571328 Jadelle formulation 33 2040-09-07
10028858 Jadelle method of use 45 2034-03-22
11090186 Jadelle method of use 45 2033-10-24
8906890 Slynd formulation 48 2031-10-22
11123299 Slynd formulation 48 2031-06-28
10987364 Slynd formulation 48 2031-06-28

Related